Abstract

There is growing evidence that cancer stem cells (CSCs), a small subpopulation of self-renewal cancer cells, are responsible for tumor growth, treatment resistance, and cancer relapse and are thus of enormous clinical interest. Here, we aimed to isolate new CSC-like cells derived from human primary non-small cell lung cancer (NSCLC) specimens and to analyze the influence of different inhibitors of NF-κB and MYC signaling on cell survival. CSC-like cells were established from three squamous cell carcinomas (SCC) and three adenocarcinomas (AC) of the lung and were shown to express common CSC markers such as Prominin-1, CD44-antigen, and Nestin. Further, cells gave rise to spherical cancer organoids. Inhibition of MYC and NF-κB signaling using KJ-Pyr-9, dexamethasone, and pyrrolidinedithiocarbamate resulted in significant reductions in cell survival for SCC- and AC-derived cells. However, inhibition of the protein–protein interaction of MYC/NMYC proto-oncogenes with Myc-associated factor X (MAX) using KJ-Pyr-9 revealed the most promising survival-decreasing effects. Next to the establishment of six novel in vitro models for studying NSCLC-derived CSC-like populations, the presented investigations might provide new insights into potential novel therapies targeting NF-κB/MYC to improve clinical outcomes in NSCLC patients. Nevertheless, the full picture of downstream signaling still remains elusive.

Highlights

  • IntroductionEven if non-small cell lung cancers (NSCLC) is less aggressive than SCLC and death rates for lung cancer in general dropped by 48% from 1990 to 2016 among males and by 23% from 2002 to 2016 among females, NSCLC prognosis is still poor, with an age-standardized 5-year net survival of approximately 19% [1]

  • We aimed for the isolation of lung cancer stem cells (LCSCs)-like cells from various non-small cell lung cancers (NSCLC)

  • BKZ-4, BKZ-5, and BKZ-6 were isolated from male donors aged 67, 79, and 74, respectively, all suffering under squamous cell carcinomas GII (Supplementary Figure S1A–C, Table S1)

Read more

Summary

Introduction

Even if NSCLC is less aggressive than SCLC and death rates for lung cancer in general dropped by 48% from 1990 to 2016 among males and by 23% from 2002 to 2016 among females, NSCLC prognosis is still poor, with an age-standardized 5-year net survival of approximately 19% [1]. This poor prognosis is mainly caused by cancer aggressiveness and therapy resistance, which is increased by genetic and phenotypic heterogeneity of lung cancer cells [5]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.